Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech regulatory approval

FDA Clears C2N Alzheimer Blood Test

Analysis based on 28 articles · First reported Aug 21, 2026 · Last updated Sep 21, 2026

Sentiment
15
Attention
4
Articles
28
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

FDA clearance of the PrecivityAD2 test expands the addressable market for blood-based Alzheimer's diagnostics, potentially benefiting C2N Diagnostics and its partners while pressuring makers of PET imaging and spinal fluid testing. Broader adoption of cheaper, less invasive testing could accelerate diagnosis and support demand for new Alzheimer's therapies, though near-term revenue impact remains limited by the test's narrow intended population.

healthcare diagnostics biotechnology

The U.S. United States — Food and Drug Administration cleared the PrecivityAD2 blood test, developed by C2N Diagnostics, a startup founded by researchers at Washington University in St. Louis, to help evaluate Alzheimer's disease in adults aged 40 and older who already show signs of cognitive decline. The test uses high-resolution mass spectrometry to measure ratios of amyloid beta and tau proteins, offering a less invasive alternative to PET brain scans and lumbar punctures. FDA clearance was supported by a study of 1,142 adults with cognitive symptoms, in which the test showed a positive predictive value of 97.6% and a negative predictive value of 93.1% compared with established reference methods. The test is intended as a diagnostic aid alongside full clinical assessment, not as a standalone diagnosis or a screening tool for healthy people. Separate reporting highlights that four Alzheimer's blood tests have now been cleared, but experts including Nicholas Ashton of Banner Health caution that symptom-free individuals should avoid such tests outside research. Research led by Mass General Brigham found that cognitively healthy older adults with very high p-tau217 levels had a 38% risk of developing cognitive impairment within five years. A study led by Josef Coresh of NYU Langone Health found that people who reached middle age without high blood pressure, type 2 diabetes and smoking lived dementia-free nearly 13 years longer than those with all three conditions. Mark Yost, a 60-year-old study volunteer, received an intermediate result. The Alzheimer s Association and United States — National Institute on Aging provide context on prevalence and disease biology, while the Mayo Clinic notes risks of spinal taps.

90 C2N Diagnostics developed and validated
50 C2N Diagnostics expanding headquarters
50 Randall J. Bateman co-founded startup C2N Diagnostics
50 David M. Holtzman co-founded startup C2N Diagnostics
40 Nicholas Ashton warned against testing
35 Josef Coresh advised aggressive prevention
10 Mark Yost volunteered for study Banner Health
priv
Developer of the cleared PrecivityAD2 test; FDA clearance validates its mass spectrometry platform and opens a larger commercial market for Alzheimer's testing.
Importance 95.0 Sentiment 60.0
govactor
Cleared the PrecivityAD2 blood test for marketing, enabling broader clinical use and setting the regulatory precedent for blood-based Alzheimer's diagnostics.
Importance 90.0 Sentiment 5.0
per
Co-founded C2N Diagnostics and co-led development of the underlying technology; stated the clearance can increase early and accurate diagnoses.
Importance 30.0 Sentiment 10.0
per
Co-founded C2N Diagnostics and co-led development of the technology behind the cleared PrecivityAD2 test.
Importance 30.0 Sentiment 10.0
priv
Conducted blood test research including cognitively normal participants; its expert cautions against testing the worried well outside studies.
Importance 25.0 Sentiment 5.0
per
WashU vice chancellor who commented on the clearance; not directly involved in the event.
Importance 20.0 Sentiment 50.0
per
Testing expert at Banner Health who cautioned that symptom-free people should not get Alzheimer's blood tests outside research studies.
Importance 20.0 Sentiment 0.0
per
Senior author of the NYU Langone Health study showing that avoiding high blood pressure, diabetes and smoking in middle age extends dementia-free life.
Importance 20.0 Sentiment 0.0
ngo
Cited for U.S. Alzheimer's prevalence data and context on lumbar puncture procedures, framing the need for less invasive testing.
Importance 15.0 Sentiment 0.0
priv
Affiliated with WashU Medicine; not directly involved in the event.
Importance 10.0 Sentiment 50.0
govactor
Its research on amyloid plaque formation was cited as scientific background supporting the biomarker approach behind the cleared tests.
Importance 10.0 Sentiment 0.0
per
Study volunteer whose intermediate result illustrates the uncertainty of Alzheimer's blood testing for people without symptoms.
Importance 10.0 Sentiment 0.0
govactor
Cited for research explaining how amyloid plaques form, providing scientific context for the cleared test.
Importance 10.0 Sentiment 0.0
priv
Mentioned as an academic hospital staffed by WashU physicians; not directly involved in the event.
Importance 5.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.